DNTH
Companies
NASDAQ
Dianthus Therapeutics Inc.
Health Care
$17.44
-$4.36 (-20.00%)
Price Chart
Overview
About DNTH
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Market Cap
$590.8M
Volume
6.6M
Avg. Volume
6.5M
P/E Ratio
-4.602761
Dividend Yield
0.00%
Employees
67.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.35
High Correlation
Volatility
High (0.83)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, DNTH shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$590.8M
Volume6.6M
P/E Ratio-4.60
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 12, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025